Company: DNLI
Filing Date: 2025-02-27
Form Type: S-3ASR
Source: 0001628280-25-008647
Chunk: 8

Company: Denali Therapeutics Inc.
Filing Date: 2025-02-27
Form: S-3ASR
Chunk 8
---
 by reference the documents set forth below that have previously been filed with the SEC:

• Our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed on February 27, 2025.

• The description of our common stock, par value $0.01 per share, contained in our registration statement on Form 8-A , filed with the SEC on November 30, 2017, including any subsequent filed amendments and reports updating such description.

All reports and other documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of this offering but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part of this prospectus from the date of the filing of such reports and documents.

You may request a free copy of any of the documents incorporated by reference in this prospectus (other than exhibits, unless they are specifically incorporated by reference in the documents) by writing or telephoning us at the following address:

<div align='center'>Denali Therapeutics Inc.

161 Oyster Point Blvd.

South San Francisco, California 94080

(650) 866-8547</div>

Exhibits to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference in this prospectus and any accompanying prospectus supplement.

The information accessible through any website referred to in this prospectus or any document incorporated herein is not, and should not be deemed to be, a part of this prospectus.

<div align='center'>8</div>

#### DENALI THERAPEUTICS INC.

#### Common Stock

#### Preferred Stock

#### Debt Securities

#### Warrants

#### Purchase Contracts

#### Units
#### ________________________________________

#### PROSPECTUS SUPPLEMENT
(To prospectus dated February 27, 2025)

#### DENALI THERAPEUTICS INC.

#### Up to $400,000,000

#### Common Stock
We, Denali Therapeutics Inc., have entered into an equity distribution agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC, as our sales agents, dated February 27, 2025, relating to the sale from time to time of shares of our common stock, par value $0.01 per share, offered by this prospectus supplement (the “equity distribution agreement”). In accordance with the terms of